Disease progression in systemic sclerosis
Open Access
- 6 January 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (3) , 1565-1567
Abstract
Dear Editor, SSc is a heterogeneous disease in which vasculopathy and fibrosis affect multiple organ systems such as the skin, gastrointestinal tract, kidneys, heart and lungs [ 1]. The clinical course of the disease can vary from rapidly progressive, resulting in generalized fibrosis of the vital organs, to a more indolent form developing over an extended period of time. For both physicians and patients, SSc represents a major clinical challenge, as prediction of the disease course remains difficult. Disease progression has been shown to occur often [ 2, 3]. However, many studies have been performed in selected subgroups of patients or have focused on specific organ domains.Keywords
This publication has 7 references indexed in Scilit:
- Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysisAnnals of the Rheumatic Diseases, 2019
- Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteriaRheumatology, 2019
- Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR modelAnnals of the Rheumatic Diseases, 2018
- Systemic sclerosisThe Lancet, 2017
- Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosisRMD Open, 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2013